Compare G & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | G | BLCO |
|---|---|---|
| Founded | 1997 | 1853 |
| Country | Bermuda | Canada |
| Employees | 140000 | N/A |
| Industry | Professional Services | Ophthalmic Goods |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.9B |
| IPO Year | 2007 | 2022 |
| Metric | G | BLCO |
|---|---|---|
| Price | $31.17 | $15.81 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 11 |
| Target Price | ★ $49.50 | $18.45 |
| AVG Volume (30 Days) | ★ 3.3M | 469.3K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.21% | N/A |
| EPS Growth | ★ 9.82 | N/A |
| EPS | ★ 0.86 | N/A |
| Revenue | $2,279,438,000.00 | ★ $5,101,000,000.00 |
| Revenue This Year | $9.20 | $8.65 |
| Revenue Next Year | $7.27 | $5.59 |
| P/E Ratio | $37.07 | ★ N/A |
| Revenue Growth | N/A | ★ 6.47 |
| 52 Week Low | $28.78 | $11.22 |
| 52 Week High | $48.64 | $18.92 |
| Indicator | G | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 39.54 | 42.13 |
| Support Level | $28.78 | $15.67 |
| Resistance Level | $38.03 | $16.41 |
| Average True Range (ATR) | 1.49 | 0.38 |
| MACD | 0.18 | -0.00 |
| Stochastic Oscillator | 40.59 | 18.00 |
Genpact Ltd is an agentic, technology-solutions company offering digital transformation, data-driven operations, and technology-enabled services across multiple industries. Its core business services include decision support services; technology services like application lifecycle management, platform customization, and support, etc; and digital operations optimizing business processes. Genpact also offers data engineering, data management, and domain-based AI and generative AI solutions; develops new technology solutions for clients; and offers agentic solutions and technology consulting services. Its reportable segments are: High Tech and Manufacturing, which generate maximum revenue, Financial Services, and Consumer and Healthcare. Geographically, it derives maximum revenue from India.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.